A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
Phase 1
Recruiting
- Conditions
- SLE (Systemic Lupus)Systemic SclerosisLupus Erythematosus, SystemicLupus NephritisInflammatory Myopathy, IdiopathicMyositisDiffuse Cutaneous Systemic Sclerosis
- Interventions
- First Posted Date
- 2025-04-13
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- CRISPR Therapeutics
- Target Recruit Count
- 80
- Registration Number
- NCT06925542
- Locations
- 🇺🇸
Research Site 1, Saint Louis, Missouri, United States
🇺🇸Research Site 4, Redwood City, California, United States
🇺🇸Research Site 2, Chicago, Illinois, United States
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies
Phase 1
Recruiting
- Conditions
- Acute Myeloid LeukemiaT Cell LymphomaB Cell Lymphoma
- Interventions
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- CRISPR Therapeutics
- Target Recruit Count
- 290
- Registration Number
- NCT06492304
- Locations
- 🇺🇸
Research Site 6, Phoenix, Arizona, United States
🇺🇸Research Site 5, Stanford, California, United States
🇺🇸Research Site 3, Boston, Massachusetts, United States
© Copyright 2025. All Rights Reserved by MedPath